-
Emma Whittle joins The RSA Group as Senior Consultant
London, UK, 24th January 2018 / Sciad Newswire / The RSA Group, a leading Life Sciences executive search firm, announced today that Emma Whittle has joined the firm as a Senior Consultant. Emma will form part of the firm’s Interims Practice, with an initial focus on the Medical Devices and Diagnostic sector. Emma brings over 15 years’ experience in executive…
-
Domainex wins award to develop GPCR drug discovery technology
Cambridge, UK, 23rd January 2018 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, has been awarded £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs). This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of…
-
Synpromics Appoints Sarah Haecker Meeks, PhD as Vice President of Business Development
Company establishes U.S. subsidiary to expand operations Edinburgh, UK, 17th January 2018 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development. Dr. Haecker Meeks brings a deep expertise in emerging technologies and business strategy focused on the design…
-
Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialization rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases
Cambridge, UK, 8th January 2017 / Sciad Newswire / Cypralis and Gilead Sciences, Inc. (“Gilead”) have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology. This is a further step in the collaboration between the parties which follows a multi-year…
-
Festival of Genomics London 2018: the landmark event making genomics mainstream
London, UK, 5th January 2018 / Sciad Newswire / This January sees the third edition of Festival of Genomics London, the largest meeting of its kind in the UK. Following two US editions of the event in the genomics hotbeds of San Diego and Boston, the London event addresses issues specific to the UK as well as wider Europe. Taking…
-
Genome Engineering and Synthetic Biology – Sneak peek inside January’s conference programme
Flanders, Belgium, 3rd January 2018 / Sciad Newswire / Bruges, Belgium will host the third edition of VIB’s Genome conference. The eight hundred-year-old Saint John’s Hospital site will welcome academics, PhD’s and companies on the 25th -26th January. The symposium will bring together some of the most highly regarded academics and companies globally, with novel technologies presented across several sessions focused on the following topics:…
-
5 reasons you should be at the Festival of Genomics London 2018!
Registration for the festival is free, so register online and secure your Festival Pass today! http://www.festivalofgenomicslondon.com/sciad To request a press pass for this event, please contact Emma Pickup | emma@sciad.com | +44 (0)20 7470 8801
-
Global Healthcare Investor Perception Report to be launched at Biotech and Money / Medtech and Money World Congress.
London, UK, 14th December 2017 / Sciad Newswire / ‘Trends and truth in life science investment’ is the latest annual report, published by Biotech and Money, to offer unique and actionable insight into investor attitudes, biases and preferences in healthcare opportunities in Europe. The perception report provides unique and powerful investor intelligence from across the investment community and…
-
Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
13th December 2017 / Sciad Newswire / Amyndas Pharmaceuticals, which is committed to developing innovative therapeutics for complement-mediated conditions, today announced positive preliminary results from a Phase 1 clinical trial of its C3-targeted complement inhibitor, AMY-101. The phase I which has just been completed, was a prospective, single-center, open-label, First-In-Human (FIH) clinical study, designed to assess the safety, tolerability,…
-
Medherant completes £3.8 million funding round
Coventry, UK, 11th December 2017 / Sciad Newswire / Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company…